Interim Phase II Data of Adcetris Against CTCL Announced

Having only recently announced plans for a pivotal Phase III trial investigating Adcetris in the treatment of cutaneous T-cell lymphoma, Seattle Genetics is announcing interim results from an investigator-sponsored Phase II clinical trial investigating Adcetris in patients with relapsed cutaneous T-cell lymphoma. They announced the data at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

Patients involved in this trial had one of two very similar subtypes of CTCL, either mycosis fungoides (MF) or Sezary syndrome (SS), although the huge majority of patients had MF.

Patients had received on average six prior therapies before the start of the trial, including an average of four prior systemic therapies. The trial's primary endpoint was and is clinical response rate, while secondary endpoints include correlation of clinical response with CD30 expression levels, duration of response, progression-free survival and safety.

The study is led by principal investigator Dr. Youn H. Kim, Professor, Department of Dermatology, and Director, Multidisciplinary Cutaneous Lymphoma Program at Stanford University School of Medicine in Stanford, CA. Key findings include:

Partial remission was achieved in 12 of 16 evaluable patients (75 percent). Stable disease was achieved by three patients. One patient had progressive disease.

Source: Genengnews

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap